Latest & greatest articles for oxycodone

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on oxycodone or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on oxycodone and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for oxycodone

1. Oxycodone vs Sufentanil in Patient-Controlled Intravenous Analgesia After Gynecological Tumor Operation: A Randomized Double-Blind Clinical Trial Full Text available with Trip Pro

Oxycodone vs Sufentanil in Patient-Controlled Intravenous Analgesia After Gynecological Tumor Operation: A Randomized Double-Blind Clinical Trial Oxycodone vs Sufentanil in Patient-Controlled Intravenous Analgesia After Gynecological Tumor Operation: A Randomized Double-Blind Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily (...) file Cancel Your RSS Feed Name of RSS Feed: Number of items displayed: Create RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Case Reports J Pain Res Actions . 2020 May 5;13:937-946. doi: 10.2147/JPR.S236933. eCollection 2020. Oxycodone vs Sufentanil in Patient-Controlled Intravenous Analgesia After Gynecological Tumor Operation: A Randomized Double-Blind Clinical Trial # , # , , , , , , Affiliations Expand Affiliations 1 Department of Anesthesia, Shaanxi Provincial

2020 EvidenceUpdates

2. Oxycodone hydrochloride (Oxyneo)

Oxycodone hydrochloride (Oxyneo) Terms of use - Canada.ca Language selection Search Search Canada.ca Search Topics menu Main Menu You are here: Terms of use From These Terms of Use govern the access and use of Clinical Information released by Health Canada for non-commercial purposes. By clicking the button “I agree” and accepting these Terms of Use and upon being granted access to the Clinical Information, you, and, if applicable, the organization on behalf of which you are accessing

2020 Health Canada - drugs and medical devices

3. Effect of Intravenous Oxycodone in Combination With Different Doses of Dexmedetomdine on Sleep Quality and Visceral Pain in Patients After Abdominal Surgery: A Randomized Study (Abstract)

Effect of Intravenous Oxycodone in Combination With Different Doses of Dexmedetomdine on Sleep Quality and Visceral Pain in Patients After Abdominal Surgery: A Randomized Study Oxycodone or dexmedetomidine (DEX) alone are widely used in clinical practice. The aim of this study was to observe the effect of 2 oxycodone and DEX combinations on postoperative sleep quality.This was a prospective and randomized clinical study. A total of 99 patients underwent laparoscopic-assisted operations (...) on stomach and intestines with general anesthesia were enrolled and randomly divided into 3 groups according to postoperative analgesic protocol (n=33 each). The analgesic protocols were as follows after the surgery. In group C, 0.6 mg/kg oxycodone alone was diluted to 100 mL in 0.9% saline. In group D1 or D2, 0.6 mg/kg oxycodone combined with 2.4 μg/kg or 4.8 μg/kg DEX was diluted to 100 mL in 0.9% saline, respectively. The intravenous patient-controlled analgesia device was set up to deliver

2018 EvidenceUpdates

4. Oxycodone

Oxycodone Top results for oxycodone - Trip Database or use your Google+ account Turning Research Into Practice ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 (...) or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for oxycodone The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence

2018 Trip Latest and Greatest

5. Effect of oxycodone patient-controlled intravenous analgesia after cesarean section: a randomized controlled study Full Text available with Trip Pro

Effect of oxycodone patient-controlled intravenous analgesia after cesarean section: a randomized controlled study Oxycodone is a semisynthetic μ-opioid receptor agonist with a potentially good analgesic efficacy in visceral pain. This study aims to compare the efficacy of oxycodone with sufentanil patient-controlled intravenous analgesia (PCIA).One hundred and twenty primiparas undergoing elective cesarean section were randomized into four groups by different drugs of PCIA: group S (sufentanil (...) 100 μg), group OS1 (sufentanil 70 μg, oxycodone 30 mg), group OS2 (sufentanil 50 μg, oxycodone 50 mg), and group O (oxycodone 100 mg). Ramosetron 0.3 mg was added to each group. In all groups, drugs were diluted to 100 mL and managed with a continuous infusion of 1 mL·h-1, a bolus dose of 2 mL, and a lockout interval of 15 min. The maximum dose of PCIA per hour was 10 mL. After surgery, pain scores, PCIA doses, and side effects were compared among groups.At all time points (6, 12, and 24 h after

2018 EvidenceUpdates Controlled trial quality: uncertain

6. Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial Full Text available with Trip Pro

Can early oral prolonged-release oxycodone with or without naloxone reduce the duration of epidural analgesia after cystectomy? A 3-arm, randomized, double-blind, placebo-controlled trial Thoracic epidural analgesia (TEA) enhances recovery after bowel surgery. Early postoperative prolonged-release oral formulation of oxycodone or oxycodone/naloxone is potentially useful as a second analgesic step to reduce the duration of TEA. We hypothesized that oxycodone would decrease the duration of TEA (...) and combined with naloxone preserve gastrointestinal function. Ninety patients undergoing open cystectomy and urinary diversion were enrolled in this randomized double-blind, three-arm, parallel-group, placebo-controlled single-center trial between September 2015 and February 2017. Exclusion criteria were known allergy to oxycodone/naloxone, pulmonary diseases, hepatopathy, and analgesics nonnaïve patients. From postoperative day 3, patients received batches with oxycodone, oxycodone/naloxone, or placebo

2018 EvidenceUpdates

7. A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-releas Full Text available with Trip Pro

A randomized, double-blind study of hydromorphone hydrochloride extended-release tablets versus oxycodone hydrochloride extended-release tablets for cancer pain: efficacy and safety in Japanese cancer patients (EXHEAL: a Phase III study of EXtended-releas In Japan, there are limited options for switching opioid analgesics. Hydromorphone is an opioid analgesic that is routinely used instead of morphine for cancer pain; however, it is not yet available in Japan. The aim of this study (...) was to assess the efficacy and safety of hydromorphone (DS-7113b) extended-release tablets in opioid-naïve patients with cancer pain not relieved by non-opioid analgesics.This was a multicenter, randomized, double-blind, parallel-group trial. A double-dummy method was used for blinding. Each randomized subject received either hydromorphone extended-release tablets plus placebo oxycodone hydrochloride extended-release tablets 4 mg/day (n=88) or placebo hydromorphone extended-release tablets plus oxycodone

2017 EvidenceUpdates Controlled trial quality: predicted high

8. Oxycodone for pain in fibromyalgia in adults. Full Text available with Trip Pro

Oxycodone for pain in fibromyalgia in adults. This review replaces part of an earlier review that evaluated oxycodone for both neuropathic pain and fibromyalgia, which has now been split into separate reviews for the two conditions. This review will consider pain in fibromyalgia only.Opioid drugs are commonly used to treat fibromyalgia, but they may not be beneficial for people with this condition. Most reviews have examined all opioids together. This review sought evidence specifically (...) for oxycodone, at any dose, and by any route of administration.To assess the analgesic efficacy and adverse events of oxycodone for treating pain in fibromyalgia in adults.We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and EMBASE for randomised controlled trials from inception to 25 July 2016. We also searched the reference lists of retrieved studies and reviews, and searched online clinical trial registries.We planned to include randomised, double-blind trials of eight

2016 Cochrane

9. Comparative Analgesic Efficacy of Oxycodone/Acetaminophen Versus Hydrocodone/Acetaminophen for Short-term Pain Management in Adults Following ED Discharge Full Text available with Trip Pro

Comparative Analgesic Efficacy of Oxycodone/Acetaminophen Versus Hydrocodone/Acetaminophen for Short-term Pain Management in Adults Following ED Discharge The objective was to test the hypothesis that oxycodone/acetaminophen provides superior analgesia to hydrocodone/acetaminophen for the treatment of acute extremity pain following emergency department (ED) discharge.This was a prospective, randomized, double-blind clinical trial of nonelderly adult ED patients with acute musculoskeletal (...) extremity pain, randomly allocated at discharge to receive oxycodone/acetaminophen (5 mg/325 mg) or hydrocodone/acetaminophen (5 mg/325 mg). The primary outcome was the between-group difference in improvement in numerical rating scale (NRS) pain scores over a 2-hour period following the most recent ingestion of study drug, obtained during telephone contact 24 hours after ED discharge. Secondary outcomes included proportionate decrease in pain, comparative side-effect profiles, and patient satisfaction.A

2015 EvidenceUpdates Controlled trial quality: predicted high

10. Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. Full Text available with Trip Pro

Naproxen With Cyclobenzaprine, Oxycodone/Acetaminophen, or Placebo for Treating Acute Low Back Pain: A Randomized Clinical Trial. Low back pain (LBP) is responsible for more than 2.5 million visits to US emergency departments (EDs) annually. These patients are usually treated with nonsteroidal anti-inflammatory drugs, acetaminophen, opioids, or skeletal muscle relaxants, often in combination.To compare functional outcomes and pain at 1 week and 3 months after an ED visit for acute LBP among (...) patients randomized to a 10-day course of (1) naproxen + placebo; (2) naproxen + cyclobenzaprine; or (3) naproxen + oxycodone/acetaminophen.This randomized, double-blind, 3-group study was conducted at one urban ED in the Bronx, New York City. Patients who presented with nontraumatic, nonradicular LBP of 2 weeks' duration or less were eligible for enrollment upon ED discharge if they had a score greater than 5 on the Roland-Morris Disability Questionnaire (RMDQ). The RMDQ is a 24-item questionnaire

2015 JAMA Controlled trial quality: predicted high

11. Tamper-Resistant Oxycodone

Tamper-Resistant Oxycodone Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types of information (...) on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners? own terms and conditions. TITLE: Tamper-Resistant Oxycodone: A Review of the Clinical Evidence and Cost- effectiveness DATE: 25

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

12. Restless legs syndrome: Oxycodone/naloxone prolonged release

Restless legs syndrome: Oxycodone/naloxone prolonged release Restless legs syndrome: Oxy Restless legs syndrome: Oxycodone/nalo codone/nalox xone one prolonged release prolonged release Evidence summary Published: 15 December 2015 nice.org.uk/guidance/esnm67 pathways K Ke ey points from the e y points from the evidence vidence The content of this evidence summary was up-to-date in December 2015. See summaries of product characteristics (SPCs), British national formulary (BNF) or the MHRA (...) or NICE websites for up-to-date information. Summary In a 12-week randomised controlled trial (RCT) in people with severe restless legs syndrome (RLS), there was a moderate improvement in the score on the International RLS study group severity rating scale with oxycodone/naloxone prolonged release tablets compared with placebo. Adverse effects such as fatigue, constipation and nausea were very common. As with all opioids, there is a risk that people may develop opioid dependence

2015 National Institute for Health and Clinical Excellence - Advice

13. Oxycodone

Oxycodone Scottish Palliative Care Guidelines - Oxycodone Scottish Palliative Care Guidelines search / / / Oxycodone Oxycodone Introduction Description : Potent, synthetic opioid analgesic; used second line. Preparations Table 1 Oxycodone In Palliative Care Oxycodone Preparations Oral Immediate release oxycodone OxyNorm® capsules Shortec® and Lynlor® also available. OxyNorm ® liquid Generic 5mg, 10mg, 20mg 1mg/ml, 10mg/ml Modified release (long acting) oxycodone OxyContin ®, Longtec®, Oxylan® (...) NB: depending on brand not all strengths available 5mg, 10mg, 15mg, 20mg, 30mg, 40mg, 60mg, 80mg, 120mg (check local guidance for preferred brand -not all strengths may be stocked) Injection Oxycodone injection OxyNorm ® injection 10mg/ml, 20mg/2ml, 50mg/ml (non- formulary in some health boards) Oxycodone in Palliative Care: Preparations - Version 1 June 2014 Indications Second line oral and injectable analgesic for moderate to severe opioid responsive pain in patients unable to tolerate oral

2015 Scottish Palliative Care Guidelines

14. Targiniq ER (oxycodone hydrochloride/naloxone hydrochloride)

Targiniq ER (oxycodone hydrochloride/naloxone hydrochloride) Drug Approval Package: Brand Name (Generic Name) NDA # Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - TARGINIQ ER (oxycodone hydrochloride/naloxone hydrochloride) Extended-Release Tablets Company: Purdue Pharma, L.P. Application No.: 205777 Approval Date: 7/23/2014 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF

2014 FDA - Drug Approval Package

15. Oxycodone

Oxycodone USE OF OXYCODONE IN PREGNANCY 0344 892 0909 USE OF OXYCODONE IN PREGNANCY (Date of issue: May 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . A corresponding patient information leaflet on is available at . Summary Oxycodone is a semisynthetic opioid analgesic administered orally (...) , intramuscularly or intravenously for the treatment of moderate to severe pain. The available data concerning the fetal effects of maternal oxycodone use in pregnancy are limited, consisting of approximately 500 pregnancies described in four uncontrolled case reports and five controlled studies. One case report and one controlled study relate to recreational oxycodone exposure specifically. The results of these studies do not currently indicate that maternal therapeutic use of oxycodone in early pregnancy

2014 UK Teratology Information Service

16. Cohort study: Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants

Cohort study: Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants Oxycodone administered as postpartum pain relief is associated with maternal report of infant central nervous system depression in breastfed infants | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time (...) . To learn more about how we use cookies, please see our . Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Oxycodone administered as postpartum pain relief is associated with maternal

2013 Evidence-Based Medicine

17. Oxycodone HCI / naloxone HCI - Pain, Moderate to severe and relief of opioid-induced constipation

Oxycodone HCI / naloxone HCI - Pain, Moderate to severe and relief of opioid-induced constipation Common Drug Review CDEC Meeting – November 16, 2011; CDEC Reconsideration – January 18, 2012 Notice of CDEC Final Recommendation – January 25, 2012 Page 1 of 6 © 2012 CADTH CDEC FINAL RECOMMENDATION OXYCODONE HYDROCHLORIDE/NALOXONE HYDROCHLORIDE RESUBMISSION (Targin – Purdue Pharma) Indication: Relief of Moderate to Severe Pain and Opioid-Induced Constipation Recommendation: The Canadian Drug (...) Expert Committee (CDEC) recommends that oxycodone hydrochloride/naloxone hydrochloride controlled release (CR) (Targin) not be listed. Reason for the Recommendation: The comparative clinical benefit of oxycodone/naloxone CR in patients with moderate to severe chronic pain and opioid-induced constipation is not established, because there are no randomized controlled trials (RCTs) comparing oxycodone/naloxone CR with less expensive opioid treatment in combination with an optimized laxative regimen

2012 Canadian Agency for Drugs and Technologies in Health - Common Drug Review

18. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine Full Text available with Trip Pro

Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release (...) evaluated the cost-effectiveness of tapentadol prolonged release, compared with oxycodone controlled release, for severe non-malignant chronic pain in patients for whom controlled-release morphine was ineffective or not tolerated. The authors concluded that tapentadol was less costly and more effective than oxycodone. The study was generally well reported and used appropriate methods. There were some issues stemming from a lack of available evidence, but the authors' conclusion seems plausible

2012 NHS Economic Evaluation Database.

19. Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study

Oral oxycodone offers equivalent analgesia to intravenous patient-controlled analgesia after total hip replacement: a randomized, single-centre, non-blinded, non-inferiority study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2011 NHS Economic Evaluation Database.

20. The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain (Abstract)

The efficacy and safety of fentanyl buccal tablet compared with immediate-release oxycodone for the management of breakthrough pain in opioid-tolerant patients with chronic pain Current clinical guidelines have identified the need for studies comparing the effect of different short-acting or rapid-onset opioids for the treatment of breakthrough pain (BTP). In this study we evaluated the efficacy and safety of treatment with fentanyl buccal tablet (FBT) in comparison with immediate-release (...) oxycodone in alleviating BTP in opioid-tolerant patients with chronic pain.In this cross-over design study, opioid-tolerant patients were randomized to open-label titration with FBT (200, 400, 600, 800 μg) followed by oxycodone (15, 30, 45, 60 mg) or vice versa for the management of BTP. After titration to a successful dose of both study drugs, patients were rerandomized to double-blind treatment for 10 BTP episodes with 1 of the already identified successful doses of study drug followed by cross-over

2011 EvidenceUpdates Controlled trial quality: predicted high